Skip to main content

CLL/SLL

4
Pipeline Programs
9
Companies
7
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
2100%
+ 7 programs with unclassified modality

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Genmab
GenmabNetherlands - Utrecht
1 program
1
EpcoritamabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT07108998Recruiting22Est. Jul 2029
Nordic Pharma
Nordic PharmaFrance - Paris
1 program
1
EpcoritamabPhase 1/2Monoclonal Antibody1 trial
Active Trials
NCT05791409Recruiting112Est. Nov 2032
Newave Pharmaceutical
Newave PharmaceuticalCA - Pleasanton
1 program
1
LP-168Phase 11 trial
Active Trials
NCT04775745Recruiting60Est. Dec 2027
Synthekine
SynthekineCA - Menlo Park
1 program
1
SYNCAR-001Phase 11 trial
Active Trials
NCT05665062Active Not Recruiting36Est. Nov 2026
BeiGene
BeiGeneChina - Beijing
1 program
First line therapyN/A1 trial
Active Trials
NCT05590702Active Not Recruiting1,000Est. Dec 2032
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
First line therapyN/A
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
First line therapyN/A
Hutchmed
HutchmedChina - Hong Kong
1 program
HMPL-760PHASE_11 trial
Active Trials
NCT05176691Withdrawn0Est. Nov 2022
InnoCare
InnoCareChina - Beijing
1 program
ICP-022PHASE_1_21 trial
Active Trials
NCT03493217Unknown100Est. Dec 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
GenmabEpcoritamab
Nordic PharmaEpcoritamab
InnoCareICP-022
SynthekineSYNCAR-001
HutchmedHMPL-760
Newave PharmaceuticalLP-168
BeiGeneFirst line therapy

Clinical Trials (7)

Total enrollment: 1,330 patients across 7 trials

NCT07108998GenmabEpcoritamab

Study of Epcoritamab as a Consolidation Therapy in CLL/SLL

Start: Aug 2025Est. completion: Jul 202922 patients
Phase 2Recruiting
NCT05791409Nordic PharmaEpcoritamab

Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL

Start: Apr 2024Est. completion: Nov 2032112 patients
Phase 1/2Recruiting
NCT03493217InnoCareICP-022

A Study to Evaluate ICP-022 in Patients With CLL/ SLL

Start: Apr 2018Est. completion: Dec 2022100 patients
Phase 1/2Unknown
NCT05665062SynthekineSYNCAR-001

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

Start: Apr 2023Est. completion: Nov 202636 patients
Phase 1Active Not Recruiting
NCT05176691HutchmedHMPL-760

HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL

Start: Feb 2022Est. completion: Nov 20220
Phase 1Withdrawn
NCT04775745Newave PharmaceuticalLP-168

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

Start: Jul 2021Est. completion: Dec 202760 patients
Phase 1Recruiting
NCT05590702BeiGeneFirst line therapy

French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma in Real-World Settings

Start: Nov 2022Est. completion: Dec 20321,000 patients
N/AActive Not Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 actively recruiting trials targeting 1,330 patients
9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.